Become an Investigator

To Apply to Become A Study Investigator or to Join Our Network, Please Provide the Following Information:

Select Studies of Interest (Optional):
- OPTIMA-G Study (_Observing _Pain _Transdermal Treatments—_Improving and _Managing _All _GI Symptoms)
- TARGET Study (_Topic_Al Silicone in _Restorin_G Scars and Burn Tissue - _Evaluating _Therapy)
- TREAT Study (_Transdermal _Relief: _Evaluating _Allergy _Topicals for Perennial Allergic Rhinitis)
Investigator Information
Name*
First Name Last Name
Credentials
Phone*
Email*
Your NPI #
Name of Clinic*
Specialty*
Practice States*
Physical Address*
Physical Address City State ZIP Code
Primary Contact Name
Primary Contact Phone
Primary Contact Email
Best Time to Contact You
How did you hear about Clarity?
Form Verification
Prove you are a human.

Scar & Burn

TARGET Study

(_Topic_Al Silicone in _Restorin_G Scars and Burn Tissue - _Evaluating _Therapy)

TARGET is a current, large-scale IRB-approved observational study on the effectiveness of topical/transdermal treatments for scar/burn characteristics, symptoms, and patient perceptions. It further evaluates the reduction of pain during the course of treatment.

Key Interim Results

69% of patients noticed reduction in scar size, results confirmed by clinician measurements, which showed a statistically significant reduction in the percentage of patients with largest (>20cm) scars from baseline (p<.003)

Over an average 128 days of scar/burn cream treatment use, patients reduced their usage of pain medications by 69% (p<.001)

Patients also reported reductions in itching (p<.001) and scar/burn interference with general activity, mood, sleep, life enjoyment, and an improvement in emotional well-being with the use of the treatment compound (p<.05)

Patients reported no serious adverse events and that the creams were safe and well-tolerated.

VIEW TARGET POSTER

Allergy

TREAT Study

(_Transdermal _Relief: _Evaluating _Allergy _Topicals for Perennial Allergic Rhinitis)

TREAT is an IRB-approved observational study to evaluate patients’ experiences and/or perceptions of prescribed transdermal allergy medications to treat seasonal and perennial allergy symptoms.

Pain

OPTIMA-G Study

(_Observing _Pain _Transdermal Treatments—_Improving and _Managing _All _GI Symptoms)

Clarity Science is conducting an IRB-approved observational study aimed at evaluating patients’ experiences and/or perceptions for those who have been prescribed a topical/transdermal pain medication. Pain and other symptoms will be evaluated by patient answers to validated assessment scales.

Become an Investigator